Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.60-9.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · TNXP
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-2.7) + peer(0.2*1.7) + term(0.0) → -0.6% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 3 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended September 30, 2026. For the three months ended September 30, 2026, the Company’s net revenue for TONMYA is estimated to be between $14.0 million and $15.0 million. As of September 30, 2026, the Company estimates that its cash and cash equivalents were approximately $162.8 million. The above information is preliminary fina…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On August 10, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2026. A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. On May 11, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2026. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended March 31, 2026, and certain preliminary financial condition information as of April 30, 2026, as set forth below: · The Company ended the quarter with approximately $185.5 million in cash and cash equivalents. As of April 30, 2026, the Company had 15,540,801 shares of common stock outstanding. · The Company’s net cash use…
of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the year and quarter ended December 31, 2025, and certain preliminary financial condition information as of January 30, 2026, as set forth below: · The Company ended the year with approximately $207.6 million in cash and cash equivalents. As of January 30, 2026, the Company had 12,793,952 shares of common stock outstanding. · The Company’s…
Results of Operations and Financial Condition On November 10, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended September 30, 2025, and certain preliminary financial condition information as of October 24, 2025, as set forth below: · The Company ended the quarter with approximately $190.1 million in cash and cash equivalents. As of October 24, 2025, the Company had 11,475,491 shares of common stock outstanding. · The Company’s net…
Results of Operations and Financial Condition. On August 11, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended June 30, 2025, and certain preliminary financial condition information as of July 25, 2025, as set forth below: · The Company ended the quarter with approximately $125.3 million in cash and cash equivalents. As of July 25, 2025, the Company had 8,745,174 shares of common stock outstanding. · The Company’s net cash used in…
Results of Operations and Financial Condition On May 12, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2025. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended March 31, 2025, and certain preliminary financial condition information as of March 31, 2025, as set forth below: • The Company ended the quarter with approximately $131.7 million in cash and cash equivalents, and 7,473,570 shares of common stock outstanding as of April 25, 2025. • The Company’s net cash used in operating…
Results of Operations and Financial Condition On March 18, 2025, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2024. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the year ended December 31, 2024, and certain preliminary financial condition information as of December 31, 2024, as set forth below: · The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024, and there were approximately 559,044,486 shares of common stock outstanding as of January 31, 2025. · The…
Results of Operations and Financial Condition On November 12, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2024. A copy of the press release that discusses these matters is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
Results of Operations and Financial Condition. Tonix Pharmaceuticals Holding Corp. (the “Company”) is disclosing selected preliminary operating results for the quarter ended September 30, 2024, and certain preliminary financial condition information as of September 30, 2024, as set forth below: · The Company had approximately $28.2 million in cash and cash equivalents as of September 30, 2024, and there are 178,584,225 shares of common stock outstanding as of October 28, 2024. · The Company’s…